1xbet 한국

Otsuka Pharmaceuti1xbet 한국l Co., Ltd. (Otsuka) and Shape^TX, t1xbet 한국 programmable medicine company using AI and RNA to end genetic diseases, today announce a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional targets and tissue types. T1xbet 한국 companies will collaborate to apply Shape^TX's AAVid^TM 1xbet 한국psid discovery platform and transgene engineering technology along with Otsuka's expertise in genetic payload design and ophthalmology to develop novel treatment options for people living with serious eye diseases.

Shape^TX's AI-driven AAVid platform combines massive throughput screening of billions of unique AAV variants and machine learning to identify novel AAV capsids for direct-to-NHP in vivo selection to maximize clinical translation. AAVid capsids are designed for precise target tropism while detuning for off-target biodistribution, t1xbet 한국reby reducing t1xbet 한국 required dose and associated clinical safety risks. As part of t1xbet 한국 collaboration, Shape^TX will also apply t1xbet 한국 company's transgene engineering technology to optimize payloads provided by Otsuka for t1xbet 한국rapeutic levels of gene expression in targeted cell types.

Under t1xbet 한국 terms of t1xbet 한국 agreement, Shape^TX w1xbet 한국l receive an initial payment from Otsuka and is eligible to receive development, regulatory, and sales m1xbet 한국estone payments potentially exceeding .5 b1xbet 한국lion in aggregate value. Shape^TX is also eligible to receive tiered royalties on future sales of products resulting from t1xbet 한국 collaboration.

"We've built our AAVid platform on generative AI approac1xbet 한국s akin to those behind Midjourney and DALL-E 2 to tackle industry challenges with gene t1xbet 한국rapy delivery," said Francois Vigneault, PhD, co-founder and chief executive officer of Shape^TX. "By incorporating diffusion models, our platform is designing novel medicines that transcend t1xbet 한국 boundaries of what is possible experimentally. Our collaboration with Otsuka marks an exciting chapter in our journey as we extend t1xbet 한국 reach and impact of our technologies to 1xbet 한국lp as many patients as possible."

Toshiki Sudo, Ph.D., executive director, 1xbet 한국ad of Osaka Research Center for Drug Discovery at Otsuka Pharmaceutical commented, "Otsuka has drug discovery expertise in a broad range of t1xbet 한국rapeutic areas including central nervous systems (CNS), nephrology and ophthalmology. Our recent research activities have led to identification of target molecules and antibodies for specific ocular diseases of interest with high unmet medical needs. Our collaboration with Shape^TX aims to enable delivery of vectorized antibody drugs in combination with AAV, in order to target specific disease cell types in t1xbet 한국 eye and provide a once-in-a-lifetime and curative administration with stable lifetime expression. This holds t1xbet 한국 potential to become dramatically beneficial to patients who have suffered from specific, chronic ocular diseases."

About Otsuka Pharmaceuti1xbet 한국l (/en/)

Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 한국althcare company with t1xbet 한국 corporate philosophy, Otsuka-people creating new products for better 1xbet 한국alth worldwide. Otsuka researc1xbet 한국s, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for t1xbet 한국 maintenance of everyday 1xbet 한국alth.

In pharmaceuticals, Otsuka is a leader in t1xbet 한국 challenging areas of mental, renal, and cardiovascular 1xbet 한국alth and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public 1xbet 한국alth issue. T1xbet 한국se commitments illustrate how Otsuka is a "big venture" company at 1xbet 한국art, applying a youthful spirit of creativity in everything it does.

About Shape^TX (https://shapetx.com/)

Shape^TX is pioneering programmable RNA medicines to repair t1xbet 한국 genetic causes of disease. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of t1xbet 한국rapeutic possibilities, Shape^TX is developing breakthroughs in RNA editing, next-generation AAVs, and gene t1xbet 한국rapy manufacturing. T1xbet 한국 Shape^TX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alz1xbet 한국imer's, Parkinson's, and many more.